AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3904435 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam (133 mg per day Week 1, 166 mg per day Week 2, 200 mg per day Weeks 3 to 12)
Number of subjects: 365
Study 3904435 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg per day Week 1, 125 mg per day Week 2, 150 mg per day Weeks 3 to 12)
Number of subjects: 365
Study 3904435 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam
Number of subjects: 365
Study 3904435 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 365
Study 30206088 — intervention group
Group type: EXPERIMENTAL
Intervention: apixaban 2.5 mg twice daily
Number of subjects: 222
Study 30206088 — intervention group
Group type: COMPARATOR
Intervention: dose-adjusted vitamin K antagonist therapy (target international normalised ratio 2.0-3.0)
Number of subjects: 222
Study 30206088 — intervention group
Group type: EXPERIMENTAL
Intervention: apixaban
Number of subjects: 222
Study 30206088 — intervention group
Group type: COMPARATOR
Intervention: dose-adjusted vitamin K antagonist therapy
Number of subjects: 222
Study 26691895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 175
Study 26691895 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study 24665869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural self‐help (CBSH)
Number of subjects: 75
Study 24665869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural self‐help augmented with implementation intentions (CBSH+)
Number of subjects: 75
Study 24665869 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 75
Study 22852870 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 2446
Study 22852870 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac SR 75 mg BID plus omeprazole 20 mg daily
Number of subjects: 2446
Study 20306614 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Rehabilitation Nursing Program (SRNP) - massage therapy 30 minutes three times a week for 3 months
Number of subjects: 26
Study 20306614 — intervention group
Group type: COMPARATOR
Intervention: Typical care (control group)
Number of subjects: 26
Study 18256079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulene-polyethylene liner
Number of subjects: 90
Study 18256079 — intervention group
Group type: COMPARATOR
Intervention: Durasul-polyethylene liner
Number of subjects: 90
Study 16986125 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 0
Study 12868789 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of unprocessed CPB volume
Number of subjects: 0
Study 12868789 — intervention group
Group type: COMPARATOR
Intervention: Transfusion of processed CPB volume
Number of subjects: 0
Study 10894284 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/3TC/IDV (indinavir) for 52 weeks
Number of subjects: 0
Study 10894284 — intervention group
Group type: COMPARATOR
Intervention: ZDV/3TC for 52 weeks
Number of subjects: 0
Study 10894284 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/3TC/NFV (nelfinavir) for 28 weeks
Number of subjects: 0
Study 10894284 — intervention group
Group type: COMPARATOR
Intervention: ZDV/3TC for 28 weeks
Number of subjects: 0
Study 10894284 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/3TC
Number of subjects: 0
Study 10894284 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/3TC/IDV
Number of subjects: 0
Study 10894284 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/3TC/PI
Number of subjects: 0
Study 8783673 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine plus cyclophosphamide/cisplatin (CP)
Number of subjects: 242
Study 8783673 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/cisplatin (CP)
Number of subjects: 242
Study 1815310 — intervention group
Group type: EXPERIMENTAL
Intervention: Valverde relaxation dragées
Number of subjects: 20
Study 1815310 — intervention group
Group type: COMPARATOR
Intervention: Bromazepam (3 mg)
Number of subjects: 20
Study 1815310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3549572 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofiltration (BF) with AN69s
Number of subjects: 39
Study 30106870 — intervention group
Group type: EXPERIMENTAL
Intervention: NIO Pediatric
Number of subjects: 75
Study 30106870 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrow EZ-IO
Number of subjects: 75
Study 30106870 — intervention group
Group type: EXPERIMENTAL
Intervention: BIG Pediatric
Number of subjects: 75
Study 30106870 — intervention group
Group type: COMPARATOR
Intervention: Jamshidi needle (manual device)
Number of subjects: 75
Study 30183779 — intervention group
Group type: EXPERIMENTAL
Intervention: Online depression intervention
Number of subjects: 445
Study 30183779 — intervention group
Group type: COMPARATOR
Intervention: Attention control intervention
Number of subjects: 445
Study 27297048 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 155
Study 27297048 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 155
Study 27297048 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list condition (WL)
Number of subjects: 155
Study 24968759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% applied preoperatively
Number of subjects: 94
Study 24968759 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% applied preoperatively
Number of subjects: 94
Study 24968759 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 0.3% (control) applied in the other eye
Number of subjects: 94
Study 22856341 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise (INT)
Number of subjects: 18
Study 22856341 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state exercise (SS)
Number of subjects: 18
Study 21344132 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 120
Study 21344132 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 120
Study 19092629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupaco positioner
Number of subjects: 66
Study 19092629 — intervention group
Group type: COMPARATOR
Intervention: ROHO positioner
Number of subjects: 66
Study 19092629 — intervention group
Group type: COMPARATOR
Intervention: OSI positioner
Number of subjects: 66
Study 17158494 — intervention group
Group type: EXPERIMENTAL
Intervention: VADO-based intervention
Number of subjects: 85
Study 17158494 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 85
Study 14503054 — intervention group
Group type: EXPERIMENTAL
Intervention: WCA + CT
Number of subjects: 148
Study 14503054 — intervention group
Group type: EXPERIMENTAL
Intervention: WCA
Number of subjects: 148
Study 14503054 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 148
Study 11101469 — intervention group
Group type: EXPERIMENTAL
Intervention: HCA supplementation (3.1 mL/kg body weight of an HCA solution at 19 g/L)
Number of subjects: 10
Study 11101469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11101469 — intervention group
Group type: EXPERIMENTAL
Intervention: HCA supplementation
Number of subjects: 10
Study 9019000 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating microscope
Number of subjects: 121
Study 9019000 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular loupe
Number of subjects: 121
Study 9019000 — intervention group
Group type: COMPARATOR
Intervention: Unaided eye
Number of subjects: 121
Study 9019000 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultants with operating microscope
Number of subjects: 121
Study 9019000 — intervention group
Group type: COMPARATOR
Intervention: Junior residents with operating microscope
Number of subjects: 121
Study 1389932 — intervention group
Group type: EXPERIMENTAL
Intervention: New Ophthalmic Delivery System (NODS) containing pilocarpine nitrate
Number of subjects: 12
Study 1389932 — intervention group
Group type: COMPARATOR
Intervention: 2% w/v pilocarpine nitrate solution
Number of subjects: 12
Study 2857025 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal morphine (13.3 mg)
Number of subjects: 40
Study 2857025 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine (13.3 mg)
Number of subjects: 40
Study 2857025 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal morphine
Number of subjects: 40
Study 2857025 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 40
Study 31023358 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-based fluid management protocol with daily assessment of BLS and diuretics (Furosemide) when BLS ≥ 15.
Number of subjects: 500
Study 31023358 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 500
Study 28935219 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion pills dispensed by trained pharmacy workers in Makwanpur district (GROUP 2)
Number of subjects: 992
Study 28935219 — intervention group
Group type: COMPARATOR
Intervention: Medical abortion pills dispensed by pharmacy workers in Chitwan district (GROUP 1)
Number of subjects: 992
Study 28935219 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion pills dispensed by trained pharmacy workers in both groups
Number of subjects: 992
Study 27615007 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of omeprazole (20 mg)
Number of subjects: 30
Study 27615007 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of omeprazole (20 mg)
Number of subjects: 30
Study 25591469 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 1.25-20 mg once daily
Number of subjects: 821
Study 25591469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 22650125 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Sanyinjiao (SP 6)
Number of subjects: 111
Study 22650125 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 111
Study 22650125 — intervention group
Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 111
Study 22650125 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 111
Study 20944049 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdated delayed prescriptions
Number of subjects: 149
Study 20944049 — intervention group
Group type: COMPARATOR
Intervention: Usual delayed prescriptions
Number of subjects: 149
Study 17974490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (0.5 mg PO at bedtime to 1 mg BID over 4 weeks)
Number of subjects: 40
Study 17974490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16208639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, ramipril, aspirin, and a combination B vitamin plus individualized cardiovascular prevention education
Number of subjects: 41
Study 16208639 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 41
Study 11978292 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (50 mg/m²) followed by misoprostol (800 micrograms vaginally)
Number of subjects: 1042
Study 11978292 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone (600 mg) followed by misoprostol (400 micrograms orally)
Number of subjects: 1042
Study 11978292 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone
Number of subjects: 1042
Study 11978292 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 1042
Study 11978292 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1042
Study 10425053 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep
Number of subjects: 75
Study 10425053 — intervention group
Group type: COMPARATOR
Intervention: Conventional smear
Number of subjects: 75
Study 8526180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with grass allergen extracts
Number of subjects: 34
Study 8526180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 2314573 — intervention group
Group type: EXPERIMENTAL
Intervention: LD children
Number of subjects: 32
Study 2314573 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study 7030442 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (640 mg/day)
Number of subjects: 53
Study 7030442 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 53
Study 7030442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 31420401 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy with intracorporeal urinary diversion
Number of subjects: 0
Study 31420401 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy
Number of subjects: 0
Study 26811130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea fiber (PF; 15 g/d)
Number of subjects: 50
Study 26811130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 50
Study 25885704 — intervention group
Group type: EXPERIMENTAL
Intervention: Waupaca Eating Smart (WES) intervention in restaurants
Number of subjects: 0
Study 25885704 — intervention group
Group type: EXPERIMENTAL
Intervention: Waupaca Eating Smart (WES) intervention in food stores
Number of subjects: 0
Study 25885704 — intervention group
Group type: COMPARATOR
Intervention: Control community (no intervention)
Number of subjects: 0
Study 25885704 — intervention group
Group type: EXPERIMENTAL
Intervention: Waupaca Eating Smart (WES) intervention overall
Number of subjects: 0
Study 23487258 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-positive women with EPDS score of 10 or higher
Number of subjects: 1396
Study 21297005 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial collagen meniscus implant (MCMI)
Number of subjects: 33
Study 21297005 — intervention group
Group type: COMPARATOR
Intervention: Partial medial meniscectomy (PMM)
Number of subjects: 33
Study 19651919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet-exercise counseling
Number of subjects: 522
Study 19651919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study 16840742 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (40% O(2), 60% N(2))
Number of subjects: 10
Study 16840742 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic helium (21% O(2), 79% He)
Number of subjects: 10
Study 16840742 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-hyperoxia (40% O(2), 60% He)
Number of subjects: 10
Study 12756385 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol spread
Number of subjects: 23
Study 12756385 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol ester spread
Number of subjects: 23
Study 10931512 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination drug with multiple doses
Number of subjects: 0
Study 10931512 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbalanced factorial design
Number of subjects: 0
Study 10931512 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted p-value approach
Number of subjects: 0
Study 9343838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-vegetable, reduced-fat, and increased-fiber diet intervention with intensive telephone counseling
Number of subjects: 93
Study 9343838 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study 8345542 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg kg‐1)
Number of subjects: 771
Study 8345542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 771
Study 3667023 — intervention group
Group type: COMPARATOR
Intervention: Normoxic conditions (sea level)
Number of subjects: 6
Study 3667023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic conditions (3000 m altitude)
Number of subjects: 6
Study 3667023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (Normoxia and Hypoxia)
Number of subjects: 6
Study 31924632 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib/celecoxib
Number of subjects: 246
Study 31924632 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 246
Study 29913033 — intervention group
Group type: COMPARATOR
Intervention: Volatile-based anaesthesia and postoperative sedation
Number of subjects: 157
Study 29913033 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based anaesthesia and postoperative sedation
Number of subjects: 157
Study 27353367 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 70
Study 27353367 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 70
Study 27353367 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 70
Study 24423370 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits (one for each guideline) at the workplace during a six-month period
Number of subjects: 220
Study 24423370 — intervention group
Group type: COMPARATOR
Intervention: Single unrelated group training session
Number of subjects: 220
Study 22565413 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral program for coping with cancer (4 weeks)
Number of subjects: 186
Study 22565413 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 186
Study 21434398 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term non-thermal radiofrequency electromagnetic field (RF EMF) exposure
Number of subjects: 0
Study 21434398 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RF EMF exposure and monotonous activity
Number of subjects: 0
Study 21434398 — intervention group
Group type: COMPARATOR
Intervention: Conditions of theta- or beta2-range domination in EEG background
Number of subjects: 0
Study 19062483 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural balloon (EB)
Number of subjects: 50
Study 19062483 — intervention group
Group type: COMPARATOR
Intervention: Air (LORA)
Number of subjects: 50
Study 15529811 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM) fortified with Enfamil Human Milk fortifier
Number of subjects: 30
Study 15529811 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM) fortified with Eoprotin
Number of subjects: 30
Study 15529811 — intervention group
Group type: COMPARATOR
Intervention: Similac 24 preterm formula
Number of subjects: 30
Study 11171650 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferential reduction of IGF‐I feedback signal strength
Number of subjects: 0
Study 11171650 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferential enhancement of IGF‐I feedback signal strength
Number of subjects: 0
Study 11171650 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective attenuation of GH‐releasing hormone feedforward signal intensity
Number of subjects: 0
Study 11171650 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective augmentation of GH‐releasing hormone feedforward signal intensity
Number of subjects: 0
Study 11171650 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective attenuation of gonadotropin‐releasing hormone feedforward signal intensity
Number of subjects: 0
Study 11171650 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective augmentation of gonadotropin‐releasing hormone feedforward signal intensity
Number of subjects: 0
Study 9628521 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprorelin acetate depot per month i.m. + 20 mg ethinyloestradiol + 0.15 mg desogestrel orally for 3 weeks (group A)
Number of subjects: 27
Study 9628521 — intervention group
Group type: COMPARATOR
Intervention: 3.75 mg leuprorelin acetate depot per month i.m. + placebo (group P)
Number of subjects: 27
Study 9628521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and P)
Number of subjects: 27
Study 9628521 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oestrogen/progestin add‐back therapy (group A)
Number of subjects: 27
Study 7511753 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril combined with acetylsalicylic acid (ASA) 236 mg
Number of subjects: 13
Study 7511753 — intervention group
Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 13
Study 3337793 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with spontaneous ventilation (nitrous oxide and halothane in oxygen)
Number of subjects: 152
Study 3337793 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with controlled ventilation (fentanyl, nitrous oxide and halothane in oxygen)
Number of subjects: 152
Study 28332259 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific pregnancy related messages
Number of subjects: 0
Study 28332259 — intervention group
Group type: COMPARATOR
Intervention: General health messages
Number of subjects: 0
Study 28571589 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician education and prospective audit and feedback interventions
Number of subjects: 0
Study 28571589 — intervention group
Group type: COMPARATOR
Intervention: Control group of general medicine inpatients
Number of subjects: 0
Study 26597295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (5 sessions, 90 min each)
Number of subjects: 180
Study 26597295 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation intervention (5 sessions, 90 min each)
Number of subjects: 180
Study 26597295 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 180
Study 23810044 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer
Number of subjects: 34
Study 23810044 — intervention group
Group type: COMPARATOR
Intervention: Conventional acid etching
Number of subjects: 34
Study 21190109 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of VR training
Number of subjects: 50
Study 21190109 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 50
Study 18422741 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption <25 g/week
Number of subjects: 1616
Study 18422741 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption 25-175 g/week
Number of subjects: 1616
Study 18422741 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption >175 g/week
Number of subjects: 1616